Macrocyclic CFTR Modulators for Protein Stabilization and Trafficking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no cure for cystic fibrosis, and existing treatments fail to effectively address the functional deficiency of the CFTR protein, leading to severe respiratory and digestive complications due to misfolded CFTR protein retention in the endoplasmic reticulum.
Innovation Solution
Development of macrocyclic compounds that stabilize the CFTR protein, potentially correcting its trafficking and function at the plasma membrane, thereby improving ionic homeostasis and mucociliary clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If small molecules are used as CF modulators to stabilize CFTR, then CFTR conformational stability is improved, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent employs high-throughput screening to systematically vary and test multiple compound parameters (chemical structure, concentration, molecular properties) to identify those that stabilize CFTR conformation. This approach transforms the complex identification problem into a systematic parameter optimization process, where computational models and automated assays evaluate numerous candidates efficiently, resolving the contradiction between achieving stability and managing identification complexity.
2Reliability
If new compounds are developed to treat CFTR-mediated conditions, then therapeutic effectiveness is improved, but the time required for drug development increases
Solution Approach 1:
The patent utilizes computational modeling and in silico screening to perform preliminary evaluation of compound candidates before experimental testing. By pre-filtering compounds based on predicted CFTR-stabilizing properties, binding affinity, and pharmacological characteristics, the approach accelerates the early stages of drug development while maintaining rigorous effectiveness criteria, thus reducing overall development time without compromising therapeutic reliability.
Solution Approach 2:
The patent establishes continuous high-throughput screening pipelines that systematically evaluate compound libraries from discovery through optimization. This continuous process maintains uninterrupted progress in identifying and refining effective CFTR modulators, eliminating gaps between research phases and enabling parallel optimization of multiple candidates simultaneously, thereby accelerating therapeutic development while ensuring effectiveness.
3Ease of operation
If existing CFTR treatments are used, then some symptom management is achieved, but no cure is available and disease progression continues
Solution Approach 1:
The patent develops small molecule compounds that act as intermediaries between the defective CFTR protein and its proper folding state. These compounds bind to CFTR and stabilize its conformation, serving as molecular mediators that enable the misfolded protein to achieve functional configuration. This intermediary approach addresses the root cause (protein misfolding) rather than merely managing symptoms, providing a pathway to cure while maintaining ease of administration through oral or inhalation delivery of small molecules.
Data Source
AI summary
The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.